According to DelveInsight assessments, total diagnosed Hunter Syndrome prevalence in the 7MM was observed to be 1,166, and for the US, the number was approximately 515.
The Hunter Syndrome epidemiology division provide insights about historical and current Hunter Syndrome patient pool and forecasted trend for every seven major countries.
DelveInsight’s ‘Hunter Syndrome – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hunter Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2017-2030
Disease Overview
Hunter Syndrome, also known as Mucopolysaccharidosis type II (MPS II), is an Iduronate 2-sulfatase (I2S) deficiency – an enzyme responsible for breaking down complex sugar molecules in the body. Deficiency or lack of the enzyme results in a build-up of complex molecules, leading to progressive and permanent damage to the tissues and organs in the body affecting mental and physical activities as well as appearances.
Hunter Syndrome Epidemiology
According to DelveInsight assessments, total diagnosed Hunter Syndrome prevalence in the 7MM was observed to be 1,166, and for the US, the number was approximately 515.
The Hunter Syndrome epidemiology division provide insights about historical and current Hunter Syndrome patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Hunter Syndrome Detailed Epidemiology Segmentation
The Hunter Syndrome epidemiology covered in the report provides historical as well as forecasted Hunter Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
The DelveInsight Hunter Syndrome report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Click to know more about the report.
Report Highlights
- 11-Year Forecast of Hunter Syndrome epidemiology
- 7MM Coverage
- Total Cases of Hunter Syndrome
- Total Cases of Hunter Syndrome according to segmentation
- Diagnosed cases of Hunter Syndrome
Table of contents
1. Key Insights
2. Executive Summary of Hunter Syndrome
3. Hunter Syndrome: Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
9. Appendix
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
*The table of contents is not exhaustive; will be provided in the final report
About DelveInsight
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: www.delveinsight.com/